Cancer Anorexia Epidemiology Forecast 2025-2034

Cancer-associated anorexia, or loss of appetite, is a distressing symptom that is commonly experienced by patients with advanced, incurable cancer. It is estimated that 70% of cancer patients with advanced stages of the disease suffer from this disabling symptom.

Cancer Anorexia Epidemiology Forecast Report Coverage

Expert Market Research's “Cancer Anorexia Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of cancer anorexia. It projects the future incidence and prevalence rates of cancer anorexia across various populations. The study covers age and type as major determinants of the cancer anorexia-affected population. The report highlights patterns in the prevalence of cancer anorexia over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Cancer Anorexia in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Cancer Anorexia: Disease Overview

Anorexia, defined as the loss of desire to eat and subsequently reduced food intake, is reported as a common symptom in cancer patients, particularly in an advanced stage of the disease. Research shows that many peptides, chemical mediators, receptors, cytokines, and hormones influence the development of anorexia in cancer patients. It is also observed that the fluctuations in plasma tumor-secreted factors and the rise in the circulating levels of proinflammatory cytokines can promote the loss of appetite.

Cancer Anorexia: Treatment Overview

Megestrol acetate, cannabinoids, and corticosteroids are some of the commonly prescribed drugs for improving appetite in cancer patients. New repurposed drugs like thalidomide, mirtazapine, anamorelin, and eicosapentaenoic acid (EPA) have demonstrated positive outcomes in enhancing food taste, reducing nausea, and improving appetite in cancer patients. Several new drugs are currently under investigation to treat cancer anorexia and address appetite loss in cancer patients.

Epidemiology

The cancer anorexia epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for cancer anorexia by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cancer anorexia and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• Anorexia, including impaired food intake and consequent body weight loss, is estimated to be diagnosed in nearly 70% of patients suffering from advanced-stage cancer.
• As per the research article published in Frontiers of Nutrition (2023), the prevalence of anorexia was the highest in patients with gastroesophageal cancer. The lowest prevalence of anorexia was found in colorectal cancer patients.
• According to Takahashi, Shunji et al. (2023), the frequency of cancer-related anorexia symptoms among patients receiving vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) treatment was reported to range from 14% to 58% for all-grade anorexia.
• In a study published in Frontiers in Nutrition (2023), the prevalence of anorexia was estimated to be 57% and 75% in a sample size of 102 patients, according to the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) and a specific anorexia questionnaire (AQ)

Country-wise Cancer Anorexia Epidemiology

The cancer anorexia epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of cancer anorexia differs between countries owing to factors such as the prevalence of cancers that are strongly linked to anorexia, healthcare infrastructure, and nutritional and dietary practices, among others. In countries with delayed diagnoses of cancer, advanced-stage cancer and associated symptoms, which also include anorexia, are likely to be more common compared to the countries with robust early cancer detection capabilities.

Country Specific Stats:

Country

Prevalence (Unit)

United States

United Kingdom

Germany

Italy

France

Spain

Japan

India

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cancer anorexia based on several factors.
• Cancer Anorexia Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of cancer anorexia are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of cancer anorexia epidemiology in the 8 major markets?
• What will be the total number of patients with cancer anorexia across the 8 major markets during the forecast period?
• What was the country-wise prevalence of cancer anorexia in the 8 major markets in the historical period?
• Which country will have the highest number of cancer anorexia patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of cancer anorexia during the forecast period of 2025-2034?
• What are the currently available treatments for cancer anorexia?
• What are the disease risks, signs, symptoms, and unmet needs of cancer anorexia?

Related Reports

Anorexia Epidemiology Forecast

Cancer Diagnostics Market